E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
Chronic inflammation, neuroglial dysfunction, and plasmalogen deficiency as a new pathobiological hypothesis addressing the overlap between post-COVID-19 symptoms and myalgic encephalomyelitis/chronic fatigue syndrome.
Chaves-Filho, Adriano Maia, Braniff, Olivia, Angelova, Angelina et al. · Brain research bulletin · 2023 · DOI
Quick Summary
This study examines how long COVID and ME/CFS may share similar problems in the body, particularly chronic inflammation (ongoing swelling and immune activation) and low levels of plasmalogens, which are protective fats found in cell membranes. The researchers propose that restoring plasmalogen levels through dietary supplements could potentially help reduce symptoms like fatigue, brain fog, and post-exertional malaise in both conditions.
Why It Matters
This work identifies a potential common biochemical pathway (plasmalogen metabolism) linking two conditions that affect millions of people worldwide and cause severe disability. If plasmalogens are indeed a key factor, it could lead to a simple, testable, and potentially safe therapeutic intervention. This represents an important bridge between basic lipid biology and clinical treatment development for ME/CFS.
Observed Findings
- Recent evidence shows significant reduction in plasmalogen content, biosynthesis, and metabolism in both ME/CFS and acute COVID-19 patients.
- Reduced plasmalogen levels are associated with increased symptom severity in ME/CFS and correlate with relevant clinical outcomes.
- Plasmalogens are consistently reduced across several conditions involving aging, chronic inflammation, and neurodegeneration.
- Chronic glial reactivity and neuroinflammation are documented features of both ME/CFS and post-COVID-19 syndrome.
Inferred Conclusions
- ME/CFS and post-COVID-19 syndrome likely share overlapping pathobiological mechanisms involving inflammation, glial dysfunction, and lipid membrane abnormalities.
- Plasmalogen deficiency represents a common pathophysiological manifestation in both conditions and may contribute to neurological and autonomic symptoms.
- Plasmalogen replacement therapy warrants investigation as a potential therapeutic strategy for ME/CFS and post-COVID-19 based on preliminary success in other neurodegenerative/neuropsychiatric disorders.
Remaining Questions
- Does plasmalogen deficiency directly cause symptoms, or is it a consequence of other disease mechanisms in ME/CFS and post-COVID-19?
- What is the optimal dose, formulation, and duration of plasmalogen replacement therapy, and does it produce clinical benefit in ME/CFS and post-COVID-19 patients?
What This Study Does Not Prove
This study does not prove that plasmalogen deficiency causes ME/CFS or post-COVID-19; it is a hypothesis proposing a mechanism based on existing literature. The paper does not present clinical trial data showing that plasmalogen replacement therapy actually works in ME/CFS patients. Correlation between reduced plasmalogens and symptoms does not establish causation, and the authors acknowledge that plasmalogen alterations have not yet been formally examined in post-COVID-19 populations.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionOrthostatic IntoleranceFatigue
Biomarker:CytokinesMetabolomicsBlood Biomarker
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:Exploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →